{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761227",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761227_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"acarbose\" outputclass=\"int-drug\">acarbose</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  acarbose  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acarbose</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761228",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761228_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"alogliptin\" outputclass=\"int-drug\">alogliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  alogliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alogliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761229",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761229_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761230",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761230_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"canagliflozin\" outputclass=\"int-drug\">canagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  canagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761231",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761231_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the exposure to   repaglinide .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761232",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761232_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">Ciclosporin</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ciclosporin   moderately   increases   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761233",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761233_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761234",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761234_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">Clopidogrel</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clopidogrel   increases   the exposure to   repaglinide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761235",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761235_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761236",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761236_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"dapagliflozin\" outputclass=\"int-drug\">dapagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  dapagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761237",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761237_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761238",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761238_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deferasirox\" outputclass=\"int-drug\">Deferasirox</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deferasirox   moderately   increases   the exposure to   repaglinide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferasirox</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761239",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761239_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"dulaglutide\" outputclass=\"int-drug\">dulaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  dulaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dulaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761240",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761240_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"empagliflozin\" outputclass=\"int-drug\">empagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  empagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Empagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761241",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761241_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   repaglinide .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761242",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761242_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"ertugliflozin\" outputclass=\"int-drug\">ertugliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  ertugliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ertugliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761243",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761243_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"exenatide\" outputclass=\"int-drug\">exenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  exenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Exenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761244",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761244_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761245",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761245_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   repaglinide .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761246",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761246_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"gemfibrozil\" outputclass=\"int-drug\">Gemfibrozil</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Gemfibrozil   increases   the exposure to   repaglinide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemfibrozil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761247",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761247_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"glibenclamide\" outputclass=\"int-drug\">glibenclamide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  glibenclamide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glibenclamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761248",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761248_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"gliclazide\" outputclass=\"int-drug\">gliclazide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  gliclazide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gliclazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761249",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761249_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"glimepiride\" outputclass=\"int-drug\">glimepiride</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  glimepiride  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glimepiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761250",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761250_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"glipizide\" outputclass=\"int-drug\">glipizide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  glipizide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glipizide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761251",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761251_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">Idelalisib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Idelalisib   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761252",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761252_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"insulins\" outputclass=\"int-drug\">insulins</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  insulins  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Insulins</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761253",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761253_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761254",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761254_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761255",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761255_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">Leflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Leflunomide   is predicted to   increase   the exposure to   repaglinide .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761256",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761256_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"letermovir\" outputclass=\"int-drug\">Letermovir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Letermovir   is predicted to   increase   the concentration of   repaglinide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761257",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761257_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"linagliptin\" outputclass=\"int-drug\">linagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  linagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761258",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761258_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"liraglutide\" outputclass=\"int-drug\">liraglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  liraglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Liraglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761259",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761259_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"lixisenatide\" outputclass=\"int-drug\">lixisenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  lixisenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lixisenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761260",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761260_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761261",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761261_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"metformin\" outputclass=\"int-drug\">metformin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  metformin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metformin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761262",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761262_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   is predicted to   decrease   the exposure to   repaglinide .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761263",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761263_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"nateglinide\" outputclass=\"int-drug\">nateglinide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  nateglinide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nateglinide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761264",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761264_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"opicapone\" outputclass=\"int-drug\">Opicapone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Opicapone   is predicted to   increase   the exposure to   repaglinide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Opicapone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761265",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761265_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   repaglinide .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761266",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761266_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   repaglinide .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761267",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761267_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"pioglitazone\" outputclass=\"int-drug\">pioglitazone</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  pioglitazone  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pioglitazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761268",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761268_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"pitolisant\" outputclass=\"int-drug\">Pitolisant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Pitolisant   is predicted to   decrease   the exposure to   repaglinide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pitolisant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761269",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761269_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   repaglinide .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761270",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761270_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   repaglinide .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761271",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761271_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761272",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761272_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">Saquinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Saquinavir   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saquinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761273",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761273_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"saxagliptin\" outputclass=\"int-drug\">saxagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  saxagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saxagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761274",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761274_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"semaglutide\" outputclass=\"int-drug\">semaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  semaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Semaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761275",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761275_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"sitagliptin\" outputclass=\"int-drug\">sitagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  sitagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sitagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761276",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761276_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"teriflunomide\" outputclass=\"int-drug\">Teriflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Teriflunomide   is predicted to   increase   the exposure to   repaglinide .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Teriflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761277",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761277_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761278",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761278_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"tolbutamide\" outputclass=\"int-drug\">tolbutamide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  tolbutamide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolbutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761279",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761279_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">Trimethoprim</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor blood glucose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Trimethoprim   slightly   increases   the exposure to   repaglinide .  Manufacturer advises avoid or monitor blood glucose .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761280",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761280_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"venetoclax\" outputclass=\"int-drug\">Venetoclax</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Venetoclax   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venetoclax</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761281",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761281_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph> and <ph otherprops=\"vildagliptin\" outputclass=\"int-drug\">vildagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  repaglinide  and  vildagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vildagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761282",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2#bnf_i1557280761282_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"repaglinide\" outputclass=\"int-heading-drug\">repaglinide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Voriconazole   is predicted to   increase   the exposure to   repaglinide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				}
			],
			"hasSearchLabel": " Repaglinide  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/repaglinide-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Repaglinide </title>"
			},
			"rdfs:label": "repaglinide"
		}
	]
}